Medicus Pharma announced that its redesigned clinical study protocol for Teverelix, a next-generation hormone antagonist for men's health, has received approval from the Institutional Review Board and conditional acceptance from the FDA. The revised study reduces patient enrollment from 390 to 126, lowering costs from over $30 million to under $10 million while maintaining scientific rigor. The FDA's feedback focused on operational details rather than core study design, allowing the company to proceed with patient recruitment soon. This streamlined approach improves efficiency and includes an interim analysis to monitor progress, marking a positive step forward for the drug's development.
A Kinder Morgan executive recently sold 5,695 shares of the company, totaling approximately $184,000, according to a recent SEC filing. This insider sale could indicate the executive's personal financial decision but does not necessarily reflect the ...
PancakeSwap now supports trading of $GMEB, a tokenized version of GameStop shares on BNB Chain, backed 1:1 by actual shares held by a regulated custodian. This allows decentralized traders to access GameStop shares anytime, unlike traditional markets...
Better Home & Finance Holding (BETR) continues to be a high-risk investment due to ongoing large losses and a steep valuation, despite some operational improvements. The company is shifting its strategy toward higher-margin home equity lines of credi...
Calumet reported a strong Q2 adjusted EBITDA of $159 million, surpassing estimates of $116 million, fueled by strong Specialty Brands performance and early sustainable aviation fuel (SAF) production at its MRL facility. Although SAF ramp-up is slower...
The Trump administration is considering a proposal to adjust capital gains taxes by subtracting inflation from gains before taxation. This would reduce the taxable amount for long-term investors, rewarding patience and reflecting real wealth creation...
